- Home
- NMCO vs PLRX Comparison
NMCO vs PLRX Comparison
Compare NMCO & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMCO | PLRX |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 560.1M | 79.9M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NMCO | PLRX |
|---|---|---|
| Price | $10.43 | $1.29 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.67 |
| AVG Volume (30 Days) | 134.6K | ★ 477.1K |
| Earning Date | 01-01-0001 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.97 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.69 | $1.09 |
| 52 Week High | $11.20 | $1.95 |
Technical Indicators
Market Signals| Indicator | NMCO | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 32.46 | 49.36 |
| Support Level | $10.12 | $1.12 |
| Resistance Level | $10.74 | $1.36 |
| Average True Range (ATR) | 0.10 | 0.07 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 2.86 | 16.67 |
Price Performance
Historical ComparisonAbout NMCO Nuveen Municipal Credit Opportunities Fund
Nuveen Municipal Credit Opps Fund is a closed-end fund. The fund's objective is to provide a high level of current income exempt from regular U.S. federal income tax and secondarily, total return. It invests in high yielding, low-to medium-quality municipal securities and uses leverage.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.